HLA-L and cancer: A total of 75 CpG sites was found to have significant effect on the risk of 10 site‐specific cancers, among which 8 CpG sites were observed to have cross‐cancer effect: cg02405476 (UBE2C), cg06639488 (EFNA1), cg07932199 (ATXN2), cg11152384 (RP11‐554A11.8), cg12101586 (CYP1A1), cg14142171 (HLA‐L), cg22533573 (WT1) and cg25727671 (HOXA7; Table 2 and Figure S1).